References
- Manjunath S, Sakhare PM. Adenosine and adenosine receptors: newer therapeutic perspective. Indian J Pharmacol. 2009;41(3):97–105. doi:10.4103/0253-7613.5520220442815
- Daval JL, Nehlig A, Nicolas F. Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci. 1991;49(20):1435–1453. doi:10.1016/0024-3205(91)90043-B1943450
- Yap SC, Lee HT. Adenosine and protection from acute kidney injury. Curr Opin Nephrol Hypertens. 2012;21(1):24–32. doi:10.1097/MNH.0b013e32834d2ec922080856
- Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol (1985). 1994;76(1):5–13. doi:10.1152/jappl.1994.76.1.58175547
- Lu J, Zhu SM, Zang WJ, et al. Protective mechanism of adenosine to the rat arterial endothelial dysfunction induced by hydrogen peroxide. Biol Pharm Bull. 2007;30(7):1206–1211. doi:10.1248/bpb.30.120617603154
- Fullerton DA, Jones SD, Grover FL, McIntyre RC Jr. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg. 1996;61(4):1118–23; discussion 1123–4. doi:10.1016/0003-4975(95)01149-8
- Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29(39):5346–5358. doi:10.1038/onc.2010.29220661219
- Tsuchiya A, Nishizaki T. Anticancer effect of adenosine on gastric cancer via diverse signaling pathways. World J Gastroenterol. 2015;21(39):10931–10935. doi:10.3748/wjg.v21.i39.1093126494951
- Yang D, Song J, Wu L, et al. Induction of senescence by adenosine suppressing the growth of lung cancer cells. Biochem Biophys Res Commun. 2013;440(1):62–67. doi:10.1016/j.bbrc.2013.09.03024051088
- Yu S, Hou D, Chen P, et al. Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells. Biochem Biophys Res Commun. 2015;460(3):759–765. doi:10.1016/j.bbrc.2015.03.10325817730
- Sureechatchaiyan P, Hamacher A, Brockmann N, Stork B, Kassack MU. Adenosine enhances cisplatin sensitivity in human ovarian cancer cells. Purinergic Signal. 2018;14(4):395–408. doi:10.1007/s11302-018-9622-730078088
- Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol. 2007;25(5):401–406. doi:10.1016/j.urolonc.2007.05.00617826660
- Stevens EV, Banet N, Onesto C, et al. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases. 2011;2(4):202–210. doi:10.4161/sgtp.2.4.1779522145092
- Cho HJ, Baek KE, Yoo J. RhoGDI2 as a therapeutic target in cancer. Expert Opin Ther Targets. 2010;14(1):67–75. doi:10.1517/1472822090344925120001211
- Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002;62(22):6418–6423.12438227
- Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 2017;14(5):5865–5870. doi:10.3892/ol.2017.692429113219
- Breier G, Blum S, Peli J, et al. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer. 2002;97(2):142–148. doi:10.1002/ijc.159911774256